Gastrointestinal Cancer—Colorectal and Anal
Giulia Martini, Stefania Napolitano, Vincenzo Famiglietti, et al.
Rechallenge treatment with anti-epidermal growth factor receptor (EGFR) drugs in patients with RAS wild type (RAS WT) metastatic colorectal cancer (mCRC) with promising antitumor activity has been recently reported. The study authors conclude that Cetuximab plus avelumab is effective and well-tolerated as a rechallenge treatment in mCRC. Skin toxicity is a clinical biomarker for the identification of RAS/BRAF mCRC patients that could benefit from anti-EGFR rechallenge. Clinical trial information: NCT04561336
Scott Kopetz, Dan Aderka, Axel Grothey, et al.
The study authors conclude from this exploratory post-hoc analysis that In the BEACON CRC study, patients with the doublet encorafenib + cetuximab for BRAF V600E-mutant mCRC demonstrated similar overall survival regardless of prior therapies or duration of prior therapy use. This analysis provides data that reflect the prior treatment landscape clinicians may face when deciding subsequent treatment regimens for patients with BRAF V600E-mutant mCRC. Clinical trial information: NCT02928224